Another excerpt from CoverageBioniche: A Home Run Buying Opportunity In Biotech 0 comments Sep 17, 2014 10:10 AM | about stocks: BNHLF Scouting for asymmetric opportunities in the small caps universe, I discovered Bioniche Life Sciences (US listing: BNHLF, Toronto: BNC.TO). This company is: •A full-fledged Phase III biotech. The test results were so good that FDA has allowed Bioniche to file for market approval in Q1 2015. •Addressing a $1 billion large and critically unmet medical need in bladder cancer with a ground-breaking technology. •About to receive an Orphan Drug Designation. •Fully funded. Bioniche has ample cash, and virtually no debt. You would expect such a company to be valued at $150 million minimum. That's a minimum, most Phase III biotechs are valued much higher. Not so in this case: the market values Bioniche at a mere $25 million. This doesn't make any sense. Bioniche is so ridiculously undervalued - exceptionally low valuation for a Phase III biotech stock - that it could be today's most undervalued biotech stock on the market.